Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies
PLOS ONE · 28.03.2024 · 19 (3) · e0300723
DOI: 10.1371/journal.pone.0300723 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 28.03.2024. Verfasst von James I Griffin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pharmaceutics, University of Washington, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, University of Washington Royalty Research Fund.
Abstract (Originalsprache)
Preclinical models of cancer are vital for assessing and predicting efficacies and toxicities of novel treatments prior to testing in human subjects. Current pancreatic tumor models exhibit variable growth rates, unpredictable tumor size after implantation in non-native tissues, or require surgical implantation. Surgical implantation in the pancreas may produce not only unpredictable tumor uptake but could also elicit additional inflammatory responses. In searching for a pancreatic carcinoma cell that can be introduced into a mouse via simple injection, we found that Pan02, a murine ductal pancreatic adenocarcinoma derived from a pancreatic lesion of a C57BL/6 mouse, inoculated peritoneally can consistently produce pancreatic tumors. This intraperitoneal, but not intravenous, introduction of Pan02 cells leads to the attachment and growth of Pan02 in the pancreas before spreading to other tissues. Time-course tissue analysis indicates that the Pan02 cells first find, infiltrate, and grow within the pancreas, producing a pancreatic tumor model. This model appears to mimic pancreatic cancer development in humans and is the first reported use of Pan02 cells to produce orthotopic pancreatic and metastatic neoplasms in a mouse model without the need for tumor implantation within matrices or survival surgeries. This orthotopic pancreatic tumor model, with consistent tumor uptake, synchronized tumor development and survival, and predictable outcomes may enable and accelerate the preclinical evaluation of treatment candidates for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Departments of Pharmaceutics, University of Washington, Seattle, Washington, United States of America.
- Departments of Bioengineering, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Qingxin Mu, Rodney J Y Ho
Förderung
- NCI NIH HHS
- National Institutes of Health
- University of Washington Royalty Research Fund
- University of Washington School of Pharmacy DMTSPR Consortium
- University of Washington School of Pharmacy Faculty Innovation Fund
Zitieren
APA
Griffin, J. I., Chen, X., Duan, L., Mu, Q., & Ho, R. J. Y. (2024). Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies. PLOS ONE, 19(3), e0300723. https://doi.org/10.1371/journal.pone.0300723
Vancouver
Griffin JI, Chen X, Duan L, Mu Q, Ho RJY. Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies. PLOS ONE. 2024;19(3):e0300723. doi:10.1371/journal.pone.0300723
BibTeX
@article{Griffin2024,
author = {Griffin, James I and Chen, Xinyue and Duan, Luqi and Mu, Qingxin and Ho, Rodney J Y},
title = {Inoculation of Pan02 cells produces tumor nodules in mouse pancreas: Characterization of a novel orthotopic pancreatic ductal adenocarcinoma tumor model for interventional studies},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {3},
pages = {e0300723},
doi = {10.1371/journal.pone.0300723}
}
EUVIMED